Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1988 1
1989 3
1990 1
1993 1
1994 1
1995 1
1996 4
1997 2
1998 1
1999 1
2001 1
2003 2
2004 1
2005 8
2006 7
2007 8
2008 7
2009 14
2010 15
2011 32
2012 29
2013 42
2014 61
2015 44
2016 32
2017 18
2018 41
2019 54
2020 58
2021 68
2022 67
2023 73
2024 58
2025 34
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

705 results

Results by year

Filters applied: . Clear all
Page 1
Histone deacetylases in virus-associated cancers.
Mirzaei H, Ghorbani S, Khanizadeh S, Namdari H, Faghihloo E, Akbari A. Mirzaei H, et al. Rev Med Virol. 2020 Jan;30(1):e2085. doi: 10.1002/rmv.2085. Epub 2019 Nov 19. Rev Med Virol. 2020. PMID: 31743548 Review.
Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.
Hallaj S, Meshkini F, Chaleshtari MG, Ghorbani A, Namdar A, Soleimanpour H, Jadidi-Niaragh F. Hallaj S, et al. Cell Immunol. 2019 Nov;345:103963. doi: 10.1016/j.cellimm.2019.103963. Epub 2019 Aug 10. Cell Immunol. 2019. PMID: 31445668 Review.
This review aimed at a brief represention of toxicities of the CAR T cells, the obstacles facing tumour treatments especially in solid tumours, and finally providing a framework for classification of the newly developed Conjugated/Split CAR-T cell technologies to ov …
This review aimed at a brief represention of toxicities of the CAR T cells, the obstacles facing tumour treatments especially in soli …
Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.
Ebrahimi S, Ghorbani E, Khazaei M, Avan A, Ryzhikov M, Azadmanesh K, Hassanian SM. Ebrahimi S, et al. J Cell Biochem. 2017 Aug;118(8):1994-1999. doi: 10.1002/jcb.25917. Epub 2017 Apr 25. J Cell Biochem. 2017. PMID: 28135008 Review.
Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer.
Gorchs L, Fernández-Moro C, Asplund E, Oosthoek M, Solders M, Ghorbani P, Sparrelid E, Rangelova E, Löhr MJ, Kaipe H. Gorchs L, et al. Cancer Res Commun. 2024 Feb 19;4(2):460-474. doi: 10.1158/2767-9764.CRC-23-0405. Cancer Res Commun. 2024. PMID: 38335302 Free PMC article.
Consistent with an antigen encounter, DP CD8+ T cells demonstrated higher proliferative rates and displayed an exhausted phenotype, characterized by elevated expression of PD-1 and TIM-3, compared with CD39-CD103- CD8+ T cells. ...Importantly, a high proportion of D …
Consistent with an antigen encounter, DP CD8+ T cells demonstrated higher proliferative rates and displayed an exhausted phenotype, c …
Neurologic complications of immune checkpoint inhibitors: A comprehensive review.
Lashkajani SZ, Azad YS, Nami MT, Darzi A, Shokouhfar M, Faizabadi SN, Diansaei M, Aghazadeh-Habashi K, Tabrizi ZA, Vanan AG. Lashkajani SZ, et al. Biomed Pharmacother. 2025 Nov;192:118669. doi: 10.1016/j.biopha.2025.118669. Epub 2025 Oct 24. Biomed Pharmacother. 2025. PMID: 41138653 Free article. Review.
ICIs, like anti-CTLA-4 (e.g., ipilimumab) and anti-PD-1/PD-L1 (e.g., pembrolizumab and nivolumab), enhance antitumor immune responses by blocking inhibitory mechanisms within T-cells. Despite benefits, ICIs can elicit immune-related adverse effects (irAEs), manifested by d …
ICIs, like anti-CTLA-4 (e.g., ipilimumab) and anti-PD-1/PD-L1 (e.g., pembrolizumab and nivolumab), enhance antitumor immune responses by blo …
Versican promotes T helper 17 cytotoxic inflammation and impedes oligodendrocyte precursor cell remyelination.
Ghorbani S, Jelinek E, Jain R, Buehner B, Li C, Lozinski BM, Sarkar S, Kaushik DK, Dong Y, Wight TN, Karimi-Abdolrezaee S, Schenk GJ, Strijbis EM, Geurts J, Zhang P, Ling CC, Yong VW. Ghorbani S, et al. Nat Commun. 2022 May 4;13(1):2445. doi: 10.1038/s41467-022-30032-0. Nat Commun. 2022. PMID: 35508608 Free PMC article.
In culture, purified versican-V1 inhibits oligodendrocyte precursor cells (OPCs) and promotes T helper 17 (Th17) polarization. Versican-V1-exposed Th17 cells are particularly toxic to OPCs. ...
In culture, purified versican-V1 inhibits oligodendrocyte precursor cells (OPCs) and promotes T helper 17 (Th17) polarization. Versic …
Nanovehicles for co-delivery of anticancer agents.
Zeinali M, Abbaspour-Ravasjani S, Ghorbani M, Babazadeh A, Soltanfam T, Santos AC, Hamishehkar H, Hamblin MR. Zeinali M, et al. Drug Discov Today. 2020 Aug;25(8):1416-1430. doi: 10.1016/j.drudis.2020.06.027. Epub 2020 Jul 2. Drug Discov Today. 2020. PMID: 32622880 Review.
705 results